Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Medicine
  • Medicine Perspective
  • Doxycycline: The...

Doxycycline: The Secret Weapon of the physician

Written By : MD brand Connect |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2021-03-19T12:30:32+05:30  |  Updated On 24 March 2022 11:46 AM IST
Doxycycline: The Secret Weapon of the physician
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

In an era of impending antibiotic resistance, anti-microbial agents continue to remain valuable, most utilized, and often most abused pharmacological agents. Scientific research and global development institutions have always kept up with the unmet needs against infections. Their powers may eventually wane in the face of dreadfully emerging antibiotic resistance.

However, clinicians contribute to making antimicrobial agents potent and viable for a longer span through a transparent review of durable antibiotics and thereby facilitating their prudent use. Doxycycline potentially remains one such antimicrobial agent in a practitioner's armamentarium.

Doxycycline – belonging to a tetracycline class of antibiotics, first became available in 1967 and has been used clinically now for more than 40 years. Even today, it remains a valuable anti-microbial agent for the management of various infections routinely encountered in daily medical practice.
Unique Pharmacological and Clinical Advantages with Use of Doxycycline
Doxycycline has activity against a very broad range of Gram-positive, Gram-negative, and 'atypical' bacteria as well as some protozoa such as malaria. It is also a useful antibiotic for prophylaxis against and treatment of several important potential biological warfare agents.(1)
The advantages of doxycycline over other members of the tetracycline family include improved oral absorption and a prolonged serum half-life. Excellent absorption and tissue distribution make it particularly useful for severely ill patients compared with other antibiotics.
An additional advantage includes a beneficial effect on the human immune system (2) and anti-inflammatory effects which also gathered the attention of the medical community for its consideration in the management of life-threatening COVID-19 infections
Doxycycline is cost-effective, widely available, and can be conveniently administered via oral or parenteral routes. This gives a practical advantage for its consideration and utilization across various practice settings in India
Doxycycline Listed in World Health Organisation (WHO) Access Group Antibiotics List
Doxycycline is listed on the "ACCESS" category with ATC Code (J01AA02). Its inclusion in this prestigious group implies that it belongs to the group of antibiotics that have activity against a "wide range of commonly encountered susceptible pathogens while also showing lower resistance potential" than antibiotics in the other groups.(3)
These valuable characteristics often form the key criteria for selecting and could eventually help to determine the clinical success of an antibiotic. Doxycycline remains one of the oldest antibiotics to make it to this distinguished basket.
2019 WHO AWaRe (Access, Watch, Reserve) Classification Database was developed based on the recommendations of the WHO Expert Committee on Selection and Use of Essential Medicines.
The objective of this categorization was to improve the use of antibiotics through antibiotic stewardship as one of the key interventions necessary to curb the further emergence and spread of antimicrobial resistance (AMR). Such categorization is also valuable for ensuring appropriate treatment. AWaRe is a useful tool to reduce antimicrobial resistance and ensure access.
The AWaRe database included details of 180 antibiotics classified as Access, Watch, or Reserve. The "ACCESS" group included antibiotics that have activity against a broad spectrum of commonly encountered susceptible microbes while also showing lower resistance potential than antibiotics in the other groups. This group includes 48 antimicrobial agents.
The "WATCH" group included antibiotics that have higher resistance potential and comprise most of the highest priority agents among the critically important antimicrobial agents that are at relatively high risk of selection of bacterial resistance. This category includes 110 antibiotics.
Lastly, the "RESERVE" group consists of antibiotics that should be reserved for treatment of confirmed or suspected infections due to multi-drug-resistant organisms. The agents included in this group need to be used as "last resort" therapeutic options, which should be accessible, but their use should be tailored to very specific patient profiles and clinical scenarios when all other alternatives have failed or are found not suitable. Twenty-two antibiotics have been included in this class.
Doxycycline Listed in WHO Essential Medicines List
Along with seeking a place in the ACCESS category of antibiotics, Doxycycline has even made it to a further smaller group of WHOs Essential Medicines List (EML) for both adults and children (4)
Evidence suggests that in order to promote the responsible use of antibiotics, the "ACCESS" group of antibiotics should make up at least 60% of national consumption. This will not only result in better use of antibiotics but also reduced costs and increased treatment access. Reaching this threshold by 2023 will contribute to countries' achieving health-related targets of the sustainable development goals and this remains the long- term vision of WHO behind the development of the AWaRE database (5) This brings out the need for clinicians to be sensitized to consider antibiotics of the "ACCESS" category, like doxycycline in the larger public health interest.
Doxycycline – Powerful Antimicrobial Agent Choice in Daily Medical Practice
Doxycycline is widely used for sexually transmitted infections, respiratory tract infections, pelvic inflammatory disease, dengue, arthropod-borne rickettsial infections, acne, and even malaria prophylaxis. Given its broad spectrum of activity and the wide array of clinical uses, including against some more obscure and difficult-to-diagnose conditions, doxycycline is sometimes referred to as the "secret weapon" of the physician.
Doxycycline at a dose of 100–200 mg dose per day is typically used in clinical practice for the treatment of various infectious diseases for decades now, and its safety profile is fairly well known.
The unique pharmacological characteristics combined with a very broad spectrum and effective microbiological profile have helped doxycycline stand the test of time and seek a place in the WHO "ACCESS" category group of antibiotics as well its essential medicines list (EML).
It will remain the responsibility of clinicians to continue to make optimal use of "access" category antibiotics like doxycycline in the interest of individual patients as well in the larger interest of public health, thus participating in the vision laid down by WHO against the impending threat of anti-microbial resistance.

The above article has been published by Medical Dialogues under the MD Brand Connect Initiative. For more details on Doxycycline, click HERE

References
Adapted from

1. Natasha E. Holmes, Safety and Efficacy Review of Doxycycline, Clinical Medicine: Therapeutics 2009:1 471–482

2. Majewski M, A current opinion on the safety and efficacy of doxycycline including parenteral administration – A review. Pol Ann Med. (2014), http://dx.doi.org/10.1016/j.poamed.2013.12.001

3. WHO releases the 2019 AWaRe Classification Antibiotics https://www.who.int/medicines/news/2019/WHO_releases2019AWaRe_classification_antibiotics/en/

4. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO

5. Adopt AWARE Portal, WHO Release, URL: https://adoptaware.org/

doxycyclineantimicrobial agentprophylaxismalariaantimicrobial resistance
MD brand Connect
MD brand Connect
    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Journal Club Today

    Universal Heart Health Advice Ignores Realities in Low-Income Countries: Study Finds

    Universal Heart Health Advice Ignores Realities in Low-Income Countries: Study Finds

    View All

    Health News Today

    Health Bulletin 24/May/2025

    Health Bulletin 24/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok